Retinoids, methotrexate and cyclosporine

Current Problems in Dermatology

Volumn 38, Issue , 2009, Pages 79-94

  Dubertret, Louis ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETRETIN; ETRETINATE; FISH OIL; FOLIC ACID; INFLIXIMAB; MAGNESIUM; METHOTREXATE; NICARDIPINE; NIFEDIPINE; RETINOID; DERMATOLOGICAL AGENT;

ANTIINFLAMMATORY ACTIVITY; BODY WEIGHT; BONE EXAMINATION; CLINICAL EXAMINATION; CONVULSION; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; EPISTAXIS; ERYTHRODERMA; FATIGUE; FEVER; FOLLICULITIS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; HAIR DISEASE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER BIOPSY; LIVER TOXICITY; LONG TERM CARE; LUNG TOXICITY; NEPHROTOXICITY; NONHUMAN; PANCYTOPENIA; PARESTHESIA; PATIENT MONITORING; PHOTOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; REVIEW; RHINITIS; SKIN INFECTION; SQUAMOUS CELL CARCINOMA; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; FEMALE; MALE;

CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; METHOTREXATE; PSORIASIS; RETINOIDS;

EID: 70350491054     PISSN: 14215721     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000232305     Document Type: Review

References (32)

1. Elias PM, Fritsch PO, Lampe M, et al: Retinoid effects on epidermal structure, differentiation, and permeability. Lab Invest 1981;454:531-540.
2. Gottlieb S, Hayes E, Gilleaudeau P, et al: Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J Cutan Pathol 1996; 23:404-418.
3. Dubertret L, Lebreton C, Touraine R: Inhibition of neutrophil migration by etretinate and its main metabolite. Br J Dermatol 1982;107:681-685.
4. Dupuy P, Bagot M, Heslan M, et al: Synthetic retinoids inhibit the antigen presenting properties of epidermal cells in vitro. J Invest Dermatol 1989;93: 455-459.
5. Gronhoj Larsen F, Steinkjer B, Jakobsen P: Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2001;145:1028-1029.
6. Dubertret L: Etretinate (Tigason, Europe; Tegisonn, USA) in psoriasis: advantages of low doses progressively increased. J Am Acad Dermatol 1985;13(part 1): 830-831.
7. Berbis P, Geiger JM, Vaisse C, Rognin C, et al: Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 1989;178:88-92.
8. Pearce DJ, Klinger S, Ziel KK, et al: Low-dose acitre-tin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol 2006;142:1000-1004.
9. Roenigk HH Jr, Callen JP, Guzzo CA, et al: Effects of acitretin on the liver. J Am Acad Dermatol. 1999;41: 584-588.
10. Weiss VC, Layden T, Spinowitz A, et al: Chronic active hepatitis associated with etretinate therapy. Br J Dermatol 1985;112:591-597.
11. Halverstam CP, Zeichner J, Lebwohl M: Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature. J Cutan Med Surg 2006;10:291-299.
12. Klinkhoff AV, Gertner E, Chalmers A, et al: Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989;16:789-791.
13. Buccheri L, Katchen BR, Karter AJ, et al: Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997;133: 711-715.
14. Lebwohl M, Drake L, Menter A, et al: Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001;45:544-553.
15. Lowenthal KE, Horn PJ, Kalb RE: Concurrent use of methotrexate and acitretin revisited. J Dermatolog Treat 2008;19:22-26.
16. Gisondi P, Del Giglio M, Cotena C, et al: Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008; 158:1345-1349.
17. Stern RS, Fitzgerald E, Ellis CN, et al: The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 1995;33:44-52.
18. Belzunegui J, Intxausti JJ, De Dios JR, et al. Absence of pulmonary fibrosis in patients with psoriasic arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol 2001;19:727-730.
19. Salim A, Tan E, Ilchyshyn A, et al: Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006;154:1169-1174.
20. Al-Awadhi A, Dale P, McKendry RJ: Pancytopenia associated with low dose methotrexate therapy: a regional survey. J Rheumatol 1993;20:1121-1125. (Pubitemid 23278160)
21. Pearce HP, Wilson BB: Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol. 1996;35:835-838.
22. Maurice PD, Maddow AJ, Green CA, et al: Monitoring patients on methotrexate: hepatic fibro-sis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005;152:451-458.
23. Berends MA, Snoek J, de Jong EM, et al: Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: FibroTest predicts the presence and FibroScan predicts the absence of significant liver fibrosis. Liver Int 2007;27:639-645.
24. Zonneveld IM, Bakker WK, Dijkstra PF, et al: Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996;132:184-187.
25. Prodanovich S, Ma F, Taylor JR, et al: Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-267.
26. Chahidi C, Morliere P, Aubailly M, et al: Photo-sensitization by methotrexate photoproducts. Photo-chem Photobiol 1983;38:317-322.
27. Laburte C, Grossman R, Abi-Rached J: Efficacy and safety of oral cyclosporine A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994;130:366-375.
28. Ho VC, Griffiths CE, Berth-Jones J: Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001;44:643-651.
29. Grossman RM, Delanay RJ, Brinton EA, et al: Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol 1991; 25:648-651.
30. Paul CF, Ho VC, McGeown C, et al: Risk of malignancies in psoriasis patients treated with cyclo-sporine: a 5 y cohort study. J Invest Dermatol 2003; 120:211-216.
31. Griffiths CE, Dubertret L, Elis CN, et al: Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004;150(suppl 67): 11-23.
32. Thai D, Brautigam M, Kaufmann R, et al: Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis: a randomised study. Dermatology 2002;205:383-388.